FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2231544295> ?p ?o ?g. }

• W2231544295 abstract "Abstract 18F-FDG PET (PET) imaging is now widely used in the management of patients with lymphoma, and has a recognised role in disease staging at diagnosis, determining response to treatment, and predicting response to autologous stem-cell transplantation (SCT). Reduced-intensity allogeneic SCT (RIT) has become an established therapy for patients with refractory or relapsed lymphoid malignancies, but the role of PET in RIT is unknown. We performed a prospective study to assess the role of PET in predicting outcome in RIT, and in directing intervention post-transplant. Sixty four patients with lymphoma were recruited from a single academic transplant centre. Transplant conditioning comprised fludarabine, melphalan and in-vivo alemtuzumab, and cyclosporine was given from day –1 to 3 months after RIT. PET and CT scans were performed pre-RIT and at 3, 6, 9, 15, 24 and 36-months post-RIT. In patients with chemotherapy-sensitive disease as assessed by CT scan, pre-transplant PET appearances did not influence the decision to proceed to transplant. Patients who progressed or relapsed (using clinical, CT or PET results), or who had mixed hematopoietic chimerism, received escalating dose donor lymphocyte infusions (DLI) in the absence of graft-versus-host disease. All 64 patients were at least 15 months (range 18–73 months) post RIT (25 follicular lymphoma, 16 Hodgkin lymphoma, 9 high-grade lymphoma, 9 mantle cell lymphoma, 5 other lymphomas), of whom 38 were PET-positive pre-transplant. With a median follow-up of 41 months, the pre-transplant PET status, (negative vs positive) had no effect on overall survival (65% vs 68%), diseasefree survival (32% vs 34%), relapse rate (56% vs 57%), and current DFS (55% vs 60%). Thirty four episodes of progression and relapse were observed in 29 patients: of these 15 (44%) were first detected by abnormal PET appearances in the presence of a normal or stable CT. No relapses were first apparent on CT and not on PET. DLI (either alone or in combination with chemotherapy or monoclonal antibody) were administered in 25 episodes of progression and relapse, and were directed by PET alone in 11 (44%). In 19 of the 25 episodes CR was achieved within 6 months of treatment. Additionally, 11 patients had PET negative residual masses on CT post-transplant. These patients were not given DLI and only 2 subsequently relapsed at the sites which were anatomically abnormal on the CT scan. Pre-transplant PET status did not influence survival or disease-free survival following allogeneic RIT. However post-transplant, PET detected progressive/recurrent lymphoma before the development of new abnormalities on CT, and thereby allowed earlier administration of immunotherapy, in 44% of episodes. The majority of patients with non-18F-FDG-avid residual abnormalities on CT post-transplant remained in durable remission, without receiving any treatment. Overall, PET changed the management in 18 out of 64 patients (28%). These findings would suggest that in contrast to autologous SCT, allogeneic transplantation using reduced intensity conditioning ± DLI may result in good outcomes for patients with chemotherapy-sensitive lymphoma, regardless of pretransplant PET appearances. Post-transplant surveillance by PET is useful for directing earlier use of immunotherapy for progressive/recurrent disease, and PET can also be used to characterise post-transplant metabolically inactive CT masses and allow appropriate withholding of DLI." @default.
• W2231544295 created "2016-06-24" @default.
• W2231544295 creator A5001865369 @default.
• W2231544295 creator A5006473672 @default.
• W2231544295 creator A5008153521 @default.
• W2231544295 creator A5039856386 @default.
• W2231544295 creator A5041242319 @default.
• W2231544295 creator A5050441808 @default.
• W2231544295 creator A5055565211 @default.
• W2231544295 creator A5085601211 @default.
• W2231544295 date "2008-11-16" @default.
• W2231544295 modified "2023-09-30" @default.
• W2231544295 title "Pre-Transplant PET Status May Not Impact on Survival Following Reduced-Intensity Allogeneic Stem-Cell Transplant for Lymphoma. However, Post-Transplant Surveillance with PET May Be Important for Directing Immunotherapy." @default.
• W2231544295 doi "https://doi.org/10.1182/blood.v112.11.3256.3256" @default.
• W2231544295 hasPublicationYear "2008" @default.
• W2231544295 type Work @default.
• W2231544295 sameAs 2231544295 @default.
• W2231544295 citedByCount "0" @default.
• W2231544295 crossrefType "journal-article" @default.
• W2231544295 hasAuthorship W2231544295A5001865369 @default.
• W2231544295 hasAuthorship W2231544295A5006473672 @default.
• W2231544295 hasAuthorship W2231544295A5008153521 @default.
• W2231544295 hasAuthorship W2231544295A5039856386 @default.
• W2231544295 hasAuthorship W2231544295A5041242319 @default.
• W2231544295 hasAuthorship W2231544295A5050441808 @default.
• W2231544295 hasAuthorship W2231544295A5055565211 @default.
• W2231544295 hasAuthorship W2231544295A5085601211 @default.
• W2231544295 hasConcept C126322002 @default.
• W2231544295 hasConcept C141071460 @default.
• W2231544295 hasConcept C143998085 @default.
• W2231544295 hasConcept C2776694085 @default.
• W2231544295 hasConcept C2776755627 @default.
• W2231544295 hasConcept C2777058707 @default.
• W2231544295 hasConcept C2777408962 @default.
• W2231544295 hasConcept C2777525834 @default.
• W2231544295 hasConcept C2778684742 @default.
• W2231544295 hasConcept C2779015954 @default.
• W2231544295 hasConcept C2779263901 @default.
• W2231544295 hasConcept C2779338263 @default.
• W2231544295 hasConcept C2911091166 @default.
• W2231544295 hasConcept C71924100 @default.
• W2231544295 hasConceptScore W2231544295C126322002 @default.
• W2231544295 hasConceptScore W2231544295C141071460 @default.
• W2231544295 hasConceptScore W2231544295C143998085 @default.
• W2231544295 hasConceptScore W2231544295C2776694085 @default.
• W2231544295 hasConceptScore W2231544295C2776755627 @default.
• W2231544295 hasConceptScore W2231544295C2777058707 @default.
• W2231544295 hasConceptScore W2231544295C2777408962 @default.
• W2231544295 hasConceptScore W2231544295C2777525834 @default.
• W2231544295 hasConceptScore W2231544295C2778684742 @default.
• W2231544295 hasConceptScore W2231544295C2779015954 @default.
• W2231544295 hasConceptScore W2231544295C2779263901 @default.
• W2231544295 hasConceptScore W2231544295C2779338263 @default.
• W2231544295 hasConceptScore W2231544295C2911091166 @default.
• W2231544295 hasConceptScore W2231544295C71924100 @default.
• W2231544295 hasLocation W22315442951 @default.
• W2231544295 hasOpenAccess W2231544295 @default.
• W2231544295 hasPrimaryLocation W22315442951 @default.
• W2231544295 hasRelatedWork W1944870578 @default.
• W2231544295 hasRelatedWork W2045476729 @default.
• W2231544295 hasRelatedWork W2132589242 @default.
• W2231544295 hasRelatedWork W2231544295 @default.
• W2231544295 hasRelatedWork W2415036482 @default.
• W2231544295 hasRelatedWork W2498568625 @default.
• W2231544295 hasRelatedWork W2553236612 @default.
• W2231544295 hasRelatedWork W2577670860 @default.
• W2231544295 hasRelatedWork W2992805415 @default.
• W2231544295 hasRelatedWork W2994174853 @default.
• W2231544295 isParatext "false" @default.
• W2231544295 isRetracted "false" @default.
• W2231544295 magId "2231544295" @default.
• W2231544295 workType "article" @default.